
Ghrelin is a peptide hormone predominantly produced in the
stomach by post translational processing after cleaving
pre-pro-Ghrelin.
Science. 2005 Nov 11;310(5750):996-9.
Lower
levels of Ghrelin expression has now been documented in various tissues including bowels,
pancreas, kidneys, the immune system, placenta, testes, pituitary, hypothalamus
Horm Res. 2003;59(3):109-17
and even chondrocytes
Endocrinology. 2004 Dec 2 Ghrelin ('Ghr' for
growth; 'relin' for releasing) was
discovered in 1999 by Kojima and colleagues
Nature. 1999 Dec 9;402(6762):656-60 and described
independently by Tomasetto from France as the motilin related peptide.
Gastroenterology. 2000 Aug;119(2):395-405
It was initially thought to be involved in GH release alone via
its action on the GHSr (Growth Hormone secretagogue receptor) but now
thought possibly to have a role in long term satiety signaling. It was
an year later since its discovery that the appetite stimulating effect
of Ghrelin was demonstrated in 3 of 4 men tested.
J Endocrinol Invest 23:493–495 Interestingly, synthetic
GH secretagogues and Ghrelin receptors were identified much before the discovery
of the endogenous growth-hormone secretagogue- Ghrelin.
Science, Vol 273, Issue 5277, 974-977 , 16 August 1996.
In fact, Hexarelin (GHRP-6) has been used as a diagnostic tool even before the
isolation of GHRH itself.
Science. 1982 Nov 5;218(4572):585-7.
Ghrelin secretion is up-regulated under
conditions of negative energy balance and down-regulated in the setting of
positive energy balance. In fact, Ghrelin is unique among gut hormones in
its increased secretion in the fasted state. Ghrelin levels
rise pre-meals and are suppressed after feeding in lean humans.
J Clin Endocrinol Metab. 2002 Jun;87(6):2984.
Hence it is
thought to be a meal initiator. This meal related rise and fall was
demonstrable even in patients who had no time cues and hence no meal
anticipation
Am J Physiol Endocrinol Metab. 2004 Mar 23.
Thus Ghrelin is the first gut hormone to have proven orexigenic
properties, and the only gut hormone with orexigenic properties on
peripheral administration.
Obese people
have a low Ghrelin level in the fasting stage which was surprising,
making the interpretation of its role more difficult. Ghrelin seems to correlate inversely with fat mass and insulin. The fact that Ghrelin levels fail to
decrease in response to feeding in the obese might suggest a disordered
control mechanism rather than a primary role for Ghrelin.
J
Endocrinol Invest. 2003 Aug;26(8):723-7. In pathologically lean people with anorexia nervosa, Ghrelin levels are raised as the fat mass is low, and fails to suppress with
food, again suggesting chronic dysregulation resulting in lack of response to
food ingestion.
J Clin Endocrinol Metab.
2003 Apr;88(4):1678-82
Ghrelin
characteristics
Ghrelin is an unusual
peptide in that it has a side chain, which is mainly responsible for its actions.
Two molecular forms are found in the stomach: a 28 amino acid form with
n-octanoylated serine in position 3, as well as a 27 amino acid des-[Gln14]
Ghrelin produced by alternative splicing of the Ghrelin gene.
J Biol Chem. 2000 Jul 21;275(29):21995-2000
Octanoylation
of the serine is crucial for activity of both forms of Ghrelin, with both forms
stimulating GH release. Thus acylated and non-acylated (des-acyl Ghrelin)
account for Ghrelin in circulation. HDL has been proposed as a
possible carrier particle for Ghrelin due to the positive correlation of Ghrelin
levels with HDL
levels.
J Clin Endocrinol Metab. 2003 Dec;88(12):5747-52. Ghrelin
clearance may primarily be effected via the kidneys as suggested by
studies
using I125 labeled Ghrelin in septic rats.
Int J Mol Med. 2003 Nov;12(5):777-81
Acylated Ghrelin disappears more rapidly
from plasma [t(1/2) of 9-13 minutes] than total Ghrelin,
[t(1/2) 27-31 minutes].
Eur J Endocrinol. 2004 Apr;150(4):447-55
Women have higher levels
of Ghrelin than men, which has been attributed to central obesity in cross
sectional studies.
J Clin Endocrinol Metab. 2004
Jan;89(1):335-43 Human Ghrelin is identical
to rat ghrelin except for two residues.
Nature.
1999 Dec 9;402(6762):656-60
Ghrelin is expressed mainly in the stomach by neuroendocrine cells in the
fundus.
Endocrinology. 2000 Nov;141(11):4255-61
Gastrectomy thus reduces Ghrelin levels by up to 65%.
J Clin Endocrinol Metab. 2001 Oct;86(10):4753-8. Ghrelin has also
been described in small and large intestine, pituitary gland, arcuate nucleus of
the hypothalamus, alpha
Diabetes. 2002 Jan;51(1):124-9
and beta cells
J Clin Endocrinol Metab. 2002 Mar;87(3):1300-8 of
the pancreatic islets, kidney, testis, placenta
Endocrinology. 2001 Feb;142(2):788-94.
and immune cells. Rat hypothalamus contains both n-octanoyl-modified and
des-acyl Ghrelin, both of which decrease with fasting as well as selective
blockade of carbohydrate metabolism with 2-deoxy-d-glucose (2-DG), in contrast
to peripheral Ghrelin.
Endocrinology.
2005 Jun;146(6):2510-6. Bioactive acylated Ghrelin has been
demonstrated to be present in saliva where it may have a role in proliferation
of oral keratinocytes, along with other salivary growth factors.
Clin Chem.
2005 Jun;51(6):997-1006
Rodent:
Short term infusions of
Ghrelin
in rats has increased food intake (as potently as NPY) with increased body
weight. Pair fed studies in rats has demonstrated that fat deposition is
increased independent of food intake. Ghrelin blockade in rats have produced
decreased food intake and weight loss. Leptin infusion SC in rats has been found
to negatively regulate Ghrelin. Short term infusions of Ghrelin intravenously,
intracerebroventricularly and
intraperitoneally increases appetite and
food intake in rats, but its physiological role is yet to be ascertained fully. Ghrelin inhibits the insulin secretion from
rat islets in vitro in a dose and glucose-dependent manner.
Chronic central
administration of Ghrelin (72 h) in rat significantly increased food intake and
body weight. Chronic central administration of Ghrelin increased both
Neuropeptide Y mRNA levels and AGRP mRNA levels in the arcuate nucleus.
Diabetes. 2001 Nov;50(11):2438-43.
Humans:
Injection of active
acylated Ghrelin at differing doses(1 and 5 microg/kg) in eighteen healthy
humans demonstrated that both the low and high
doses of Ghrelin strongly stimulated GH release and increased hunger in a
dose-dependent manner.
Eur J Endocrinol. 2004 Apr;150(4):447-55. A
difference in induction of insulin sensitivity has been noted depending on
whether acylated or nonacylated or a combination of the two is administered.
J Clin Endocrinol Metab. 2004 Oct;89(10):5035-42
Acute
intravenous Ghrelin administration (1.0 microg/kg) in nine obese women [BMI 36.3 +/- 2.3]
and seven normal women (BMI 20.3 +/-
1.7 ) was studied. J
Clin Endocrinol Metab. 2003 Nov;88(11):5478-83. In Obese women and non obese women,
Ghrelin significantly increased GH, PRL, ACTH, and cortisol levels.
The GH response to Ghrelin in obese women was 55% lower than in non obese
women. In normal weight women, Ghrelin increased glucose but did not change
insulin levels. In the obese women, Ghrelin increased glucose and reduced
insulin (P < 0.05). Does this mean that it is not Ghrelin hypo secretion, but
a resistance to or decreased responsiveness to Ghrelin that produces the
metabolic abnormalities of obesity?
Ghrelin infusion in 7 healthy normal
lean subjects induced transient decrease in spontaneous insulin secretion but
not the insulin response to a glucose load. Also Ghrelin infusion raised basal
glucose but not the glucose rise during OGTT.
J Clin Endocrinol Metab. 2003 Sep;88(9):4268-72.
In a study quoted above involving
acute intravenous Ghrelin administration (1.0 microg/kg) in nine obese women [BMI 36.3 +/- 2.3] and seven normal women
(BMI 20.3 +/- 1.7), Ghrelin increased
glucose in the normal weight women, without a change in insulin levels. In the obese women, Ghrelin increased
glucose and reduced insulin.
J Clin Endocrinol Metab. 2003 Nov;88(11):5478-83.
Ghrelin
increases hunger and food intake in both lean and obese subjects.
Int J Obes Relat Metab Disord. 2005 May 24